标题
The ADAMs family of proteases as targets for the treatment of cancer
作者
关键词
-
出版物
CANCER BIOLOGY & THERAPY
Volume 17, Issue 8, Pages 870-880
出版商
Informa UK Limited
发表日期
2016-04-27
DOI
10.1080/15384047.2016.1177684
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Clinical benefit of INCB7839, a potent and selective ADAM inhibitor, in combination with trastuzumab in patients with metastatic HER2+ breast cancer.
- (2017) R. C. Newton et al. JOURNAL OF CLINICAL ONCOLOGY
- ADAM Proteases and Gastrointestinal Function
- (2016) Jennifer C. Jones et al. Annual Review of Physiology
- ADAM-family metalloproteinases in lung inflammation: potential therapeutic targets
- (2015) Daniela Dreymueller et al. AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
- Targeting HER2 for the Treatment of Breast Cancer
- (2015) Mothaffar F. Rimawi et al. Annual Review of Medicine
- Extracellular Juxtamembrane Segment of ADAM17 Interacts with Membranes and Is Essential for Its Shedding Activity
- (2015) Stefan Düsterhöft et al. BIOCHEMISTRY
- ADAM10: a new player in breast cancer progression?
- (2015) Maeve Mullooly et al. BRITISH JOURNAL OF CANCER
- Targeting ADAM-17 with an inhibitory monoclonal antibody has antitumour effects in triple-negative breast cancer cells
- (2015) F Caiazza et al. BRITISH JOURNAL OF CANCER
- Notch signaling: An emerging therapeutic target for cancer treatment
- (2015) Xun Yuan et al. CANCER LETTERS
- The multiple roles of epidermal growth factor repeatO-glycans in animal development
- (2015) Amanda R Haltom et al. GLYCOBIOLOGY
- Loss of ADAM17 is associated with severe multiorgan dysfunction
- (2015) Robert H.J. Bandsma et al. HUMAN PATHOLOGY
- The Cytoplasmic Domain of A Disintegrin and Metalloproteinase 10 (ADAM10) Regulates Its Constitutive Activity but Is Dispensable for Stimulated ADAM10-dependent Shedding
- (2015) Thorsten Maretzky et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Distinct Intracellular Domain Substrate Modifications Selectively Regulate Ectodomain Cleavage of NRG1 or CD44
- (2015) Liseth M. Parra et al. MOLECULAR AND CELLULAR BIOLOGY
- A Monoclonal Antibody to ADAM17 Inhibits Tumor Growth by Inhibiting EGFR and Non-EGFR-Mediated Pathways
- (2015) J. Rios-Doria et al. MOLECULAR CANCER THERAPEUTICS
- ADAM15 targets MMP9 activity to promote lung cancer cell invasion
- (2015) DAN-DAN DONG et al. ONCOLOGY REPORTS
- iRhoms 1 and 2 are essential upstream regulators of ADAM17-dependent EGFR signaling
- (2015) Xue Li et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- ADAM8 as a drug target in pancreatic cancer
- (2015) Uwe Schlomann et al. Nature Communications
- ADAM10 mediates trastuzumab resistance and is correlated with survival in HER2 positive breast cancer
- (2015) Katharina Feldinger et al. Oncotarget
- ADAM10 and ADAM17: New Players in Trastuzumab Resistance
- (2015) Michael J. Duffy et al. Oncotarget
- ADAM9 Promotes Lung Cancer Metastases to Brain by a Plasminogen Activator-Based Pathway
- (2014) C.-Y. Lin et al. CANCER RESEARCH
- Targeting the Sheddase Activity of ADAM17 by an Anti-ADAM17 Antibody D1(A12) Inhibits Head and Neck Squamous Cell Carcinoma Cell Proliferation and Motility via Blockage of Bradykinin Induced HERs Transactivation
- (2014) Yanchao Huang et al. International Journal of Biological Sciences
- N-Glycosylation Regulates ADAM8 Processing and Activation
- (2014) Srimathi Srinivasan et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- A Disintegrin and Metalloprotease 17 Dynamic Interaction Sequence, the Sweet Tooth for the Human Interleukin 6 Receptor
- (2014) Stefan Düsterhöft et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The Effect of Disintegrin-Metalloproteinase ADAM9 in Gastric Cancer Progression
- (2014) J. M. Kim et al. MOLECULAR CANCER THERAPEUTICS
- ADAM10 regulates proliferation, invasion, and chemoresistance of bladder cancer cells
- (2014) Lin Fu et al. TUMOR BIOLOGY
- Metalloproteinase-disintegrin ADAM12 is associated with a breast tumor-initiating cell phenotype
- (2013) Hui Li et al. BREAST CANCER RESEARCH AND TREATMENT
- Deadly crosstalk: Notch signaling at the intersection of EMT and cancer stem cells
- (2013) Ingrid Espinoza et al. CANCER LETTERS
- ADAM8 expression in invasive breast cancer promotes tumor dissemination and metastasis
- (2013) Mathilde Romagnoli et al. EMBO Molecular Medicine
- ADAM12 redistributes and activates MMP-14, resulting in gelatin degradation, reduced apoptosis and increased tumor growth
- (2013) R. Albrechtsen et al. JOURNAL OF CELL SCIENCE
- ADAM17, shedding, TACE as therapeutic targets
- (2013) Stefan Rose-John PHARMACOLOGICAL RESEARCH
- Cancer Genome Landscapes
- (2013) B. Vogelstein et al. SCIENCE
- ADAM-17: a novel therapeutic target for triple negative breast cancer
- (2012) P. M. McGowan et al. ANNALS OF ONCOLOGY
- A novel bispecific single-chain antibody for ADAM17 and CD3 induces T-cell-mediated lysis of prostate cancer cells
- (2012) Kosuke Yamamoto et al. BIOCHEMICAL JOURNAL
- ADAM17-overexpressing breast cancer cells selectively targeted by antibody–toxin conjugates
- (2012) Ahmad Trad et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Ectodomain shedding and ADAMs in development
- (2012) S. Weber et al. DEVELOPMENT
- The membrane-proximal domain of A Disintegrin and Metalloprotease 17 (ADAM17) is responsible for recognition of the interleukin-6 receptor and interleukin-1 receptor II
- (2012) Inken Lorenzen et al. FEBS LETTERS
- Effect of ADAM28 on Carcinoma Cell Metastasis by Cleavage of von Willebrand Factor
- (2012) Satsuki Mochizuki et al. JNCI-Journal of the National Cancer Institute
- Anti-Tumour Effects of a Specific Anti-ADAM17 Antibody in an Ovarian Cancer Model In Vivo
- (2012) Frances M. Richards et al. PLoS One
- Tumor Necrosis Factor Signaling Requires iRhom2 to Promote Trafficking and Activation of TACE
- (2012) C. Adrain et al. SCIENCE
- Sequence-Specific Recognition of a PxLPxI/L Motif by an Ankyrin Repeat Tumbler Lock
- (2012) C. Xu et al. Science Signaling
- Global Characterization of the SRC-1 Transcriptome Identifies ADAM22 as an ER-Independent Mediator of Endocrine-Resistant Breast Cancer
- (2011) D. McCartan et al. CANCER RESEARCH
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- The disintegrin/metalloproteinase Adam10 is essential for epidermal integrity and Notch-mediated signaling
- (2011) S. Weber et al. DEVELOPMENT
- Epidermal Growth Factor (EGF) Ligand Release by Substrate-specific A Disintegrin and Metalloproteases (ADAMs) Involves Different Protein Kinase C (PKC) Isoenzymes Depending on the Stimulus
- (2011) Michelle Dang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Identification and biology of α-secretase
- (2011) Valérie Vingtdeux et al. JOURNAL OF NEUROCHEMISTRY
- The emergence of ADAM10 as a regulator of lymphocyte development and autoimmunity
- (2011) David R. Gibb et al. MOLECULAR IMMUNOLOGY
- Inflammatory Skin and Bowel Disease Linked toADAM17Deletion
- (2011) Diana C. Blaydon et al. NEW ENGLAND JOURNAL OF MEDICINE
- PKCα and PKCδ Regulate ADAM17-Mediated Ectodomain Shedding of Heparin Binding-EGF through Separate Pathways
- (2011) Marie Kveiborg et al. PLoS One
- Cross-domain inhibition of TACE ectodomain
- (2011) C. J. Tape et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- ADAM17: a molecular switch to control inflammation and tissue regeneration
- (2011) Jürgen Scheller et al. TRENDS IN IMMUNOLOGY
- ADAM10 is the physiologically relevant, constitutive α-secretase of the amyloid precursor protein in primary neurons
- (2010) Peer-Hendrik Kuhn et al. EMBO JOURNAL
- ADAM15 to α5β1 integrin switch in colon carcinoma cells: A late event in cancer progression associated with tumor dedifferentiation and poor prognosis
- (2010) Claire Toquet et al. INTERNATIONAL JOURNAL OF CANCER
- Tumor Necrosis Factor- (TNF- ) Regulates Shedding of TNF- Receptor 1 by the Metalloprotease-Disintegrin ADAM8: Evidence for a Protease-Regulated Feedback Loop in Neuroprotection
- (2010) J. W. Bartsch et al. JOURNAL OF NEUROSCIENCE
- Direct Activation of TACE-Mediated Ectodomain Shedding by p38 MAP Kinase Regulates EGF Receptor-Dependent Cell Proliferation
- (2010) Pinglong Xu et al. MOLECULAR CELL
- Active-site determinants of substrate recognition by the metalloproteinases TACE and ADAM10
- (2009) Cristina I. Caescu et al. BIOCHEMICAL JOURNAL
- The role of ADAMs in disease pathophysiology
- (2009) Michael J. Duffy et al. CLINICA CHIMICA ACTA
- Role of ADAMs in Cancer Formation and Progression
- (2009) M. J. Duffy et al. CLINICAL CANCER RESEARCH
- ADAM28 as a Target for Human Cancers
- (2009) Satsuki Mochizuki et al. CURRENT PHARMACEUTICAL DESIGN
- Potential late-onset Alzheimer's disease-associated mutations in the ADAM10 gene attenuate α-secretase activity
- (2009) Minji Kim et al. HUMAN MOLECULAR GENETICS
- ADAM10, the Rate-limiting Protease of Regulated Intramembrane Proteolysis of Notch and Other Proteins, Is Processed by ADAMS-9, ADAMS-15, and the γ-Secretase
- (2009) Thomas Tousseyn et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- ADAM10 Is Upregulated in Melanoma Metastasis Compared with Primary Melanoma
- (2009) Sophia B. Lee et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Selective Use of ADAM10 and ADAM17 in Activation of Notch1 Signaling
- (2009) E. C. Bozkulak et al. MOLECULAR AND CELLULAR BIOLOGY
- ADAMs 10 and 17 Represent Differentially Regulated Components of a General Shedding Machinery for Membrane Proteins Such as Transforming Growth Factor α, L-Selectin, and Tumor Necrosis Factor α
- (2009) Sylvain M. Le Gall et al. MOLECULAR BIOLOGY OF THE CELL
- Autoactivation of human ADAM8: a novel pre-processing step is required for catalytic activity
- (2008) Troii Hall et al. BIOSCIENCE REPORTS
- Synergistic Inhibition with a Dual Epidermal Growth Factor Receptor/HER-2/neu Tyrosine Kinase Inhibitor and a Disintegrin and Metalloprotease Inhibitor
- (2008) L. Witters et al. CANCER RESEARCH
- TACE/ADAM-17: A Component of the Epidermal Growth Factor Receptor Axis and a Promising Therapeutic Target in Colorectal Cancer
- (2008) N. B. Merchant et al. CLINICAL CANCER RESEARCH
- ADAM10 as a Target for Anti-Cancer Therapy
- (2008) Marcia Moss et al. CURRENT PHARMACEUTICAL BIOTECHNOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search